One more step toward treatment of PARP inhibitor-resistant ovarian cancers is a research paper published in Oncotarget (2023). On theSindex it has a DataRank of 0.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: R21 CA263003
NCI NIH HHS
Grant: P50 CA136393
National Institutes of Health
Grant: 5P50CA136393-10
Mayo Clinic Ovarian Cancer SPORE
National Institutes of Health
Grant: 5R21CA263003-02
PG545 synergizes with PARP inhibitors in ovarian cancer to disrupt DNA repair through modulation of DEK-RAD51 axis
FWCI
0.00
Citation Percentile
0.3%
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals